2025年以来,一品红药业的股价涨势尤为特殊。据统计,自今年年初以来,一品红的股价从16元攀升至60元水平,涨幅260%左右。业界猜测扶摇直上的走势源自其在痛风领域的布局,即URAT1抑制剂氘泊替诺雷。高尿酸血症或痛风,在中国乃至全球都是一个尚未充分开掘的市场。鉴于高尿酸血症及痛风患病率上升,2033年中国市场规模有望达到21亿美元。今年痛风这个治疗赛道越发显得火热:卫材的新一代URAT1抑制剂...
Source Link2025年以来,一品红药业的股价涨势尤为特殊。据统计,自今年年初以来,一品红的股价从16元攀升至60元水平,涨幅260%左右。业界猜测扶摇直上的走势源自其在痛风领域的布局,即URAT1抑制剂氘泊替诺雷。高尿酸血症或痛风,在中国乃至全球都是一个尚未充分开掘的市场。鉴于高尿酸血症及痛风患病率上升,2033年中国市场规模有望达到21亿美元。今年痛风这个治疗赛道越发显得火热:卫材的新一代URAT1抑制剂...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.